Syndrome of attention deficit with hyperactivity as an interdisciplinary problem. Mexidol® children with ADHD

Time codes:
  • 03:45

    Comorbidity and diagnosis

  • 07:26

    Pathogenesis and treatment

  • 11:05

    Examples of behavior of children with ADHD

  • 24:27

    Treatment of ADHD

  • 29:57

    The effectiveness of Mexidol®

  • 35:44

    Safety and effectiveness

  • 46:02

    ADHD and its connection with computer dependence

  • 53:25

    Diagnosis and treatment of ADHD

  • 01:06:33

    The effect of ADHD on school academic performance

  • 01:13:22

    Hypoxia and ADHD

  • 01:15:45

    The mechanism of action of the drug Mexidol®

  • 01:21:00

    Recommendations for the use of Mexidol

  • 01:34:11

    Sports and ADHD

  • 01:37:55

    Problems with studies and ADHD

  • 01:41:06

    Drug therapy and ADHD

Greek Severin Vyacheslavovich - MD, associate professor, head. Department of Psychiatry and Narcology of the FSBEI in St. Petersburg PMPMU of the Ministry of Health of Russia

Suvorinova Natalya Yuryevna - Ph.D., Associate Professor of the Department of Neurology, Neurosurgery and Medical Genetics named after Acad. L.O. Badalyana PF FGAOU in RNIMU them. N.I. Pirogova of the Ministry of Health of Russia, neurologist KDC RDKB

Announcement:

The syndrome of attention deficit and hyperactivity (ADHD) is a common clinical disorder in children and can manifest itself in the form of impaired attention, manifestations of hyperactivity and impulsiveness. ADHD should be differentiated with other conditions, such as behavior disorder, anxiety disorders, separation anxiety, social alarm and others. ADHD has a complex pathogenesis associated with genetic and biological factors. The approach to treatment requires an interdisciplinary assessment and should include safe drugs aimed at reducing oxidant stress and protecting brain cells from free radicals. Drug treatment using the drug Mexidol® showed high effectiveness in the treatment of ADHD in children.

Block of articles on this topic

The results of a multicenter dual blind randomized placebo-controlled clinical study on the assessment of the effectiveness and safety of the drug Mexidol in the treatment of attention deficit syndrome in children (mega)
The possibility of using Mexidol in neuropediatrics

Authors:
N.N. Zavadenko, N.Yu. Suvorinova, A.N. Zavadenko

FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

The course of school adaptation in children with syndrome of attention deficiency with hyperactivity against the background of the use of Mexidol

Authors:
I.S. Potapova, N.V. Khrina, M.V. Protopopova

Original and reproduced drugs: what do the clinician need to know?

Author:
A.V. Schulkin, A.A. Filimonova
FSBEI in the Ryazan State Medical University of the Ministry of Health of Russia, Ryazan, Russia

Information is intended for medical and pharmaceutical workers. This information cannot serve as a replacement for a doctor’s consultation.

Source of photos and images Shutterstock.com